Page last updated: 2024-12-04

7-chlorokynurenic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-chlorokynurenic acid: selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

7-chlorokynurenic acid : A quinolinemonocarboxylic acid that is quinaldic acid which is substituted by a hydroxy group at position 4 and by a chlorine at position 7. It is a potent NMDA glutamate receptor antagonist which antagonizes the strychnine-insensitive glycine site of the NMDA receptor. It also prevents neurodegeneration produced by quinolinic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID1884
CHEMBL ID311389
CHEBI ID63965
SCHEMBL ID157187
MeSH IDM0159713

Synonyms (94)

Synonym
einecs 241-913-6
nsc 149792
7-chloro-kynurenic acid
7-chloro-4-hydroxyquinoline-2-carboxylic acid
HMS3266C21
BRD-K84214706-001-03-2
DIVK1C_006816
EU-0100362
SPECTRUM_001451
BSPBIO_003542
NCGC00024511-01
lopac-c-121
NCGC00015183-01
tocris-0237
BPBIO1_001230
SPECTRUM5_001162
BIOMOL-NT_000199
nsc-149792
18000-24-3
nsc149792
NCGC00024511-05
NCGC00024511-03
KBIO2_004499
KBIOSS_001931
KBIOGR_000348
KBIO3_002826
KBIO2_001931
KBIO2_007067
KBIO1_001760
SPBIO_001399
SPECTRUM2_001470
SPECPLUS_000720
SPECTRUM4_000084
SPECTRUM3_001942
SPECTRUM1502059
LOPAC0_000362
7-chlorokynurenic acid
NCGC00024511-06
NCGC00024511-04
NCGC00024511-02
NCGC00015183-03
C-121
7-cl-kyna
CHEMBL311389 ,
chebi:63965 ,
kynurenic acid, 7-chloro-
7-chloro-4-hydroxy-quinoline-2-carboxylic acid (7-chloro-kynurenate)
7-chloro-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid
bdbm50005001
7-chloro-4-hydroxy-quinoline-2-carboxylic acid
7-chloro-4-oxo-1h-quinoline-2-carboxylic acid
7-cka
s7936qon2k ,
unii-s7936qon2k
CCG-39180
NCGC00015183-05
NCGC00015183-06
NCGC00015183-07
NCGC00015183-04
NCGC00015183-02
7-chloro-4-hydroxy-2-carboxyquinoline
2-quinolinecarboxylic acid, 7-chloro-4-hydroxy-
AKOS023250576
SCHEMBL157187
DTXSID7042568
7-chloro-4-oxo-1,4-dihydroquinoline-2-carboxylic acid
77474-31-8
CKA ,
2-quinolinecarboxylicacid,7-chloro-4-hydroxy-
mfcd00069227
7-chlorokynurenic acid, 97%
J-011490
SR-01000076227-1
SR-01000076227-3
sr-01000076227
CS-0020453
HY-100811
AS-52646
FT-0705682
HMS3675C11
HMS3411C11
Q15634175
BRD-K84214706-001-04-0
A17070
SB21215
7-chlorokynurenic-acid
C-285
7-chloro-4-oxo-1h-quinoline-2-carboxylic acid.
ageloline a
7cka
P15444
7-chloro-4-oxo-1,4-dihydroquinoline-2-carboxylicacid
PD022025
SY097385

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Activation of the coagulation system and adverse effects of homocysteine on the endothelium and vessel wall are believed to underlie disease pathogenesis."( Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor.
Arnelle, DR; Choi, YB; D'Emilia, DM; Kim, WK; Kumar, S; Lipton, SA; Rayudu, PV; Stamler, JS, 1997
)
0.3
" Agonists of the glycine recognition site of NMDA receptors (D-serine and D-alanine) did not have any toxic effect in hippocampal cultures, whereas competitive blockade of the glycine site by 7-chlorokynurenic acid was neuroprotective."( Glycine-induced neurotoxicity in organotypic hippocampal slice cultures.
Barth, A; Barth, L; Newell, DW; Nguyen, LB, 2005
)
0.52

Bioavailability

ExcerptReferenceRelevance
") did not affect cGMP responses, suggesting poor bioavailability in brain."( Indole-2-carboxylates, novel antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine recognition sites: in vivo characterization.
Cler, JA; Cordi, AA; Dappen, MS; Emmett, MR; Gray, NM; Iyengar, S; Mick, SJ; Monahan, JB; Rao, TS; Wood, PL, 1993
)
0.29

Dosage Studied

ExcerptRelevanceReference
" In dose-response studies, ifenprodil attenuated the NMDA-induced increase in medium GABA at all ages tested with an Imax of 10 microM."( Developmental differences in antagonism of NMDA toxicity by the polyamine site antagonist ifenprodil.
Nicklas, WJ; Zeevalk, GD, 1992
)
0.28
" DTT treatment also markedly shifted the dose-response curve of NMDA to the left."( Redox modulation of N-methyl-D-aspartate-stimulated neurotransmitter release from rat brain slices.
Blair, R; Woodward, JJ, 1991
)
0.28
" Analysis of dose-response curves for the action of glycine on responses to 100 microM-NMDA revealed a 3-fold higher potency of glycine for potentiation of peak versus steady-state responses, with concentrations for half-activation of 134 and 382 nM, respectively."( Modulation of N-methyl-D-aspartic acid receptor desensitization by glycine in mouse cultured hippocampal neurones.
Benveniste, M; Mayer, ML; Vyklický, L, 1990
)
0.28
" The dose-response effects of glutamate and serine were studied on the population spikes evoked in the granular cell layer."( Serine released from hippocampal slices during deprivation of oxygen and glucose enhances the effects of glutamate on neuronal function.
Hirai, H; Okada, Y, 1993
)
0.29
"Chronic dosing with the glycine partial NMDA agonist, 1-aminocyclopropanecarboxylic acid (ACPC) elicited an altered allosteric regulation of cortical NMDA receptor binding."( Chronic dosing with 1-aminocyclopropanecarboxylic acid, a glycine partial agonist, modulates NMDA inhibition of muscarinic-coupled PI hydrolysis in rat cortical slices.
Boje, KM; Lakhman, SS, 1998
)
0.3
" N-Methyl-D-aspartate (NMDA)-evoked currents were greatly and reversibly potentiated by bath application of nefiracetam resulting in a bell-shaped dose-response curve."( Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons.
Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
NMDA receptor antagonistAny substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
quinolinemonocarboxylic acidAny aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02510.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.01780.540617.639296.1227AID2364; AID2528
cytochrome P450 2C9 precursorHomo sapiens (human)Potency31.62280.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.83260.001815.663839.8107AID894
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency6.30960.01789.637444.6684AID588834
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.03980.039816.784239.8107AID995
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency15.84890.00106.000935.4813AID943
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.00180.891312.067628.1838AID1487
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)153.00000.00011.617910.0000AID92493
Glutamate receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)153.00000.00011.700010.0000AID92493
Glutamate receptor 3Rattus norvegicus (Norway rat)IC50 (µMol)153.00000.00011.700010.0000AID92493
Glutamate receptor 4Rattus norvegicus (Norway rat)IC50 (µMol)153.00000.00011.700010.0000AID92493
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00700.98217.0000AID93717
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)67.88800.00071.600310.0000AID143473; AID144895; AID144896; AID145260
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00701.01327.0000AID93717
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00701.01327.0000AID93717
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)67.88800.00071.630610.0000AID143473; AID144895; AID144896; AID145260
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)67.88800.00061.525710.0000AID143473; AID144895; AID144896; AID145260
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)67.88800.00071.747210.0000AID143473; AID144895; AID144896; AID145260
Glutamate receptor ionotropic, kainate 4Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00701.01327.0000AID93717
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)67.88800.00071.741110.0000AID143473; AID144895; AID144896; AID145260
Glutamate receptor ionotropic, kainate 5Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00701.01327.0000AID93717
Vesicular glutamate transporter 3Rattus norvegicus (Norway rat)Ki590.00000.04000.11500.1900AID216240
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)67.88800.00071.741110.0000AID143473; AID144895; AID144896; AID145260
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)67.88800.00071.741110.0000AID143473; AID144895; AID144896; AID145260
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)Kb35.00000.59003.33007.0000AID163310; AID187000
Glutamate receptor 2Rattus norvegicus (Norway rat)Kb35.00000.59003.17337.0000AID163310; AID187000
Glutamate receptor 3Rattus norvegicus (Norway rat)Kb35.00000.59003.17787.0000AID163310; AID187000
Glutamate receptor 4Rattus norvegicus (Norway rat)Kb35.00000.59003.28567.0000AID163310; AID187000
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)Kb50.00001.29004.96339.0000AID91453
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Kb7.00000.00592.09697.0000AID143250; AID145182; AID187000
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)Kb50.00001.29004.96339.0000AID91453
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)Kb50.00001.29004.04509.0000AID91453
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Kb7.00000.00592.41137.0000AID143250; AID145182; AID187000
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Kb7.00000.00592.41137.0000AID143250; AID145182; AID187000
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Kb7.00000.00592.41137.0000AID143250; AID145182; AID187000
Glutamate receptor ionotropic, kainate 4Rattus norvegicus (Norway rat)Kb50.00001.29004.96339.0000AID91453
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Kb7.00000.00592.41137.0000AID143250; AID145182; AID187000
Glutamate receptor ionotropic, kainate 5Rattus norvegicus (Norway rat)Kb50.00001.29004.96339.0000AID91453
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Kb7.00000.00592.41137.0000AID143250; AID145182; AID187000
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Kb7.00000.00592.41137.0000AID143250; AID145182; AID187000
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID143765Selectivity ratio for CPP and gly NMDA binding1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
AID92493Inhibition of [3H]-AMPA binding to AMPA receptor of rat cortical membrane1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID144467Binding activity against N-methyl-D-aspartate glutamate receptor in rat brain homogenate using [3H]CPP as the radioligand.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: new antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID144895Inhibition of [3H]-glutamate binding to N-methyl-D-aspartate glutamate receptor of rat cortical membranes1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID229653Selectivity ratio as the ratio of IC50 values for [3H]CPP/[3H]-gly1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: new antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex.
AID203505Human serum albumin index was measured by retention time on an HPLC column containing human albumin1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists.
AID145260In vitro inhibition of [3H]glycine at NMDA receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID145182Apparent dissociation constant of [3H]glycine from N-methyl-D-aspartate glutamate receptor in rat cortical slice preparation1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID143250In vitro inhibition of cortical slice at NMDA receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID91453Apparent dissociation constant of [3H]kainate from Ionotropic glutamate receptor ionotropic kainate was determined in rat cortical slice preparation1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID143472Activity against rat cortical and hippocampal membrane strychnine-insensitive N-methyl-D-aspartate glutamate receptor 1 using [3H]-gly1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
AID143157Antagonistic activity against N-methyl-D-aspartate glutamate receptor induced cGMP in rat cerebellar slices..1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: new antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID144468Binding activity against N-methyl-D-aspartate glutamate receptor in rat brain homogenate using [3H]-glycine as the radioligand.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: new antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex.
AID93717Inhibition of [3H]-kainic acid binding to kainate receptor of rat cortical membrane1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID216240Evaluated for competitive inhibition against Vesicular glutamate transporter (VGLUT), and Ki value was reported.2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport.
AID143473Affinity for the glycine binding site on rat N-methyl-D-aspartate glutamate receptor 1, determined by displacement of the glycine site antagonist [3H]L-689,560 from rat cortical membranes1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists.
AID143163Concentration required to inhibit 50% of the specific binding of [3H]glycine to NMDA receptor prepared from rat cerebral cortex and hippocampus1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
2-Carboxytetrahydroquinolines. Conformational and stereochemical requirements for antagonism of the glycine site on the NMDA receptor.
AID143781Activity against rat cortical and hippocampal membrane N-methyl-D-aspartate glutamate receptor 1/2A/2B/2C/2D using [3H]CPP1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
AID163310Apparent dissociation constant of [3H]AMPA from quisqualate receptor of rat cortical slice1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID187000Functional antagonistic potency assessed by determination of the apparent dissociation constant for antagonism of the depolarizations induced by NMDA and AMPA in rat cortical slice preparation1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
2-Carboxytetrahydroquinolines. Conformational and stereochemical requirements for antagonism of the glycine site on the NMDA receptor.
AID144896Inhibition of [3H]glycine binding to glycine site of N-methyl-D-aspartate glutamate receptor in rat cortical membranes1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID144181Apparent dissociation constant of [3H]glycine from N-methyl-D-aspartate glutamate receptor in rat cortical slice preparation expressed as log values.1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.
AID19623Partition coefficient (logP)1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists.
AID227647Activity was determined by inhibition of glutamate stimulated accumulation of cyclic GMP in neonatal rat cerebral slices.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID493017Wombat Data for BeliefDocking1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (242)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (3.72)18.7374
1990's172 (71.07)18.2507
2000's42 (17.36)29.6817
2010's16 (6.61)24.3611
2020's3 (1.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.13 (24.57)
Research Supply Index5.51 (2.92)
Research Growth Index5.88 (4.65)
Search Engine Demand Index20.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other243 (98.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]